Max von Zedtwitz – författare

The volume focuses on the issue of globalization of research and development (R&D) in China.China has become the number one choice of R&D for multination corporations (MNCs), according to a recent survey. Many of the largest MNCs in the world, such as Microsoft, GE, GM, HP, Motorola, and Lucent, among hundred of others, have established R&D facilities. The phenomenon has become a hot issue among policy debates in many countries regarding job outsourcing, national and regional competitiveness, and China. This book examines the issue of foreign R&D, particularly, those from MNCs in China: the drivers, missions, locations, management challenges, policies, and implications for China’s innovation system.This book was previously published as a special issue of the Asian Pacific Business Review.

The volume focuses on the issue of globalization of research and development (R&D) in China.China has become the number one choice of R&D for multination corporations (MNCs), according to a recent survey. Many of the largest MNCs in the world, such as Microsoft, GE, GM, HP, Motorola, and Lucent, among hundred of others, have established R&D facilities. The phenomenon has become a hot issue among policy debates in many countries regarding job outsourcing, national and regional competitiveness, and China. This book examines the issue of foreign R&D, particularly, those from MNCs in China: the drivers, missions, locations, management challenges, policies, and implications for China’s innovation system.This book was previously published as a special issue of the Asia Pacific Business Review.

This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures.

Dieses Buch untersucht und beleuchtet die wichtigsten Herausforderungen, denen sich die pharmazeutische Industrie in einem zunehmend wettbewerbsorientierten Umfeld mit inflationären F&E-Investitionen und verschärftem Kostendruck stellen muss. Die Autoren stellen drei Quellen der pharmazeutischen Innovation vor: neue Managementmethoden in der Arzneimittelentwicklung, neue Technologien als Voraussetzung für Spitzenforschung und -entwicklung und neue Formen der Zusammenarbeit und Internationalisierung, wie z. B. Open Innovation in den frühen Phasen der Forschung und Entwicklung. Neue Modelle und Methoden werden anhand von Fallbeispielen aus Europa, den USA und Asien illustriert. Diese dritte, vollständig überarbeitete Auflage wurde erweitert, um die neuesten Entwicklungen im Bereich der offenen und kollaborativen Innovation, die größere strategische Bedeutung von Risikokapital und Investitionen in der Frühphase sowie die neue Palette an aufkommenden Technologien, die jetzt in der pharmazeutischen Innovation eingesetzt werden, zu berücksichtigen.

This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures.

This book analyses the relationships among product safety strategy and culture, concurrent engineering, new product development (NPD) processes and product safety performance.